Keyword: AVEO Pharmaceuticals
In a "Groundhog Day" scenario, the FDA has once more slapped down Aveo Oncology’s attempt to get its ill-fated cancer drug on the U.S. market.
The agency advised Aveo against filing a NDA after data failed to address the concerns that led it to reject the drug in renal cell carcinoma in 2013.
The action cuts short a relationship that was starting to sour amid the slow progress of the treatment for severe, cancer-related weight loss.
The spectacular rehabilitation of Aveo's cancer drug tivozanib continues with E.U. approval as a treatment for advanced kidney cancer.
Aveo Pharmaceuticals’ troubled tivozanib is on the cusp of winning approval in Europe, sending its stock on a tear.
Aveo inches closer to completing a crucial trial of its main asset tivozanib—almost four years after the FDA turned down the kidney cancer drug.
Not wanting to allow a $4 million SEC penalty to get them down, Aveo Oncology is getting right back into the clinic with its multi-failed cancer candidate tivozanib to be used with Bristol’s PD-1 immunotherapy med Opdivo (nivolumab).
